[Long-term experience with prophylactic BCG therapy of high risk patients with superficial bladder tumors]. / Fokozott kockázatú felületes hólyagtumoros betegek profilaktikus intravesicalis BCG-kezelésével szerzett hosszú távú tapasztalataink.

The authors analysed the data of 45 high risk patients with recurrent superficial transitional cell cancer of the bladder who received after radical transurethral resection prophylactic intracavitaly BCG treatment among 1987-1995. They observed complete remission (28/45), partial remission (10/45), non responders (7/45). The progression rate was (12/45). In case of recurrence they made a second cure with high dose BCG. They deemed the maintenance therapy useful. They reviewed their experiences with the patients who had a B2 stage before. They gave account of their result after complementary chemotherapy with Pallagicin. One serious pulmonary side effect, was detected, which had been treated successfully with antituberculotic drugs.

[Immunotherapy of superficial bladder tumors in a hospital department]. / Felületes hólyagtumorok immunoterápiája osztályunkon.

Since 1988 27 patients with bladder cancer - in the T1, G1, G2 stage - have been treated by intra-cavitally applied BCG (Pasteur). The follow-up period was 12-62 months. There was no relapse in 18 cases (66%) in 4 cases (16%) increase the average relapse rate, in 5 cases the treatment was unsuccessful. These results suggest that the treatment is effective, affordable and occur few complications.